Carthage, MO—Stratum Nutrition announced in a press release that eggshell membrane ingredient NEM has become an internationally recognized joint health ingredient as supported in a large, double-blind, placebo-controlled Clinical Trial from Turkey.
The Journal of Arthritis recently published this study, which evaluated the efficacy of Stratum’s NEM ingredient in 166 subjects diagnosed with Grade 2 or Grade 3 osteoarthritis of the knee.
The study was conducted at eight different university medical centers in Turkey. Within seven days, patients showed improvement; by day 30, both knee pain and stiffness had improved by more than 30% in the NEM-treated subjects.
Related: Help for Creaky Bones and Achy Joints
Probiotic Strain BLIS M18 Receives FDA Letter of No Objection
From the Ground Up: Standardization, Regulation, Innovation
The study employed a single-crossover design to compare subjects taking NEM for 90 days versus subjects taking NEM for 60 days: placebo subjects began taking NEM after day 30. In the 90-day NEM group, 71% of subjects say at least a 15% decrease in pain; in the 60-day NEM group, 53% of subjects saw at least a 15% decrease in pain.
Kevin J. Ruff, Ph.D., Sr. Director of Scientific & Regulatory Affairs for Stratum, said in the release: “This is the largest study conducted to date involving NEM, and we are please d that it was supportive of its fast time to efficacy, even in subjects with moderate to severe arthritis. This, combined with its cartilage protecting effects recently demonstrated in healthy individuals, makes NEM the perfect adjunctive therapy for those with joint issues.”